Showing results (191-200 of 362) with videos related to
Sort By:
Pageof 37
Diabetes Care|October 19, 2013
Elevated HbA1c and fasting plasma glucose in predicting diabetes incidence among older adults: are two better than one?Kasia J Lipska, Silvio E Inzucchi, Peter H Van Ness, et al.Circulation|November 1, 2017
Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke)Shadi Yaghi, Karen L Furie, Catherine M Viscoli, et al.Journal of the American Heart Association|April 19, 2024
Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National CohortsCyprien A Rivier, Julian N Acosta, Audrey C Leasure, et al.The International Journal of Cardiovascular Imaging|October 20, 2021
Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trialMads Ersbøll, Mikkel Jürgens, Philip Hasbak, et al.American Heart Journal|November 22, 2021
Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers about treatment of heart failure (PROMPT-HF)Lama Ghazi, Nihar R Desai, Michael Simonov, et al.Journal of Diabetes and Its Complications|September 5, 2018
Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR)Suzanne V Arnold, Darren K McGuire, Silvio E Inzucchi, et al.JAMA Neurology|October 5, 2017
Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial InfarctionWalter N Kernan, Catherine M Viscoli, Jennifer L Dearborn, et al.Circulation|April 14, 2020
Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart AssociationSuzanne V Arnold, Deepak L Bhatt, Gregory W Barsness, et al.Cardiovascular Diabetology|June 20, 2014
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Bernard Zinman, Silvio E Inzucchi, John M Lachin, et al.Diabetes|January 21, 2022
Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE TrialEmil Wolsk, Mikkel Jürgens, Morten Schou, et al.Pageof 37